Advances of anaplastic lymphoma kinase in non-small cell lung cancer / 国际肿瘤学杂志
Journal of International Oncology
;
(12): 592-595, 2014.
Article
Dans Chinois
| WPRIM
| ID: wpr-456225
ABSTRACT
Targeted therapy is the most prospective part of the research related to the treatment of non-small cell lung cancer(NSCLC). After epidermal growth factor receptor(EGFR),anaplastic lymphoma kinase (ALK)gene is expected to become a new target in the treatment of NSCLC. Moreover,several related resear-ches suggest that ALK inhibitor(crizotinib)is effective for treatment of ALK-rearranged NSCLC. Therefore,it is important to review the detection method of ALK gene,clinicopathologic features and the research progress of ALK inhibitor for the individual treatment of NSCLC.
Texte intégral:
Disponible
Indice:
WPRIM (Pacifique occidental)
langue:
Chinois
Texte intégral:
Journal of International Oncology
Année:
2014
Type:
Article
Documents relatifs à ce sujet
MEDLINE
...
LILACS
LIS